In This Issue of Archives of Internal Medicine

T his large study of elderly individuals with diabetes compared the rates of cardiovascular outcomes between patients initiating pioglitazone vs rosiglitazone treatment. Patients starting therapy with either of these 2 medications were similar at baseline, but those receiving rosiglitazone had greater allcause mortality and more congestive heart failure during follow-up compared with pioglitazone users. The risks of myocardial infarction and stroke did not differ significantly between these groups. This study helps inform the treatment choice between these thiazolidinediones.